MedTrace Logo

Zambia SiVET MMR Tdap-IPV

NCT02589678 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2017-11-06

No results posted yet for this study

Summary

Participants will receive vaccination for measles, mumps, and rubella (MMR) and tetanus, diphtheria, pertussis, and inactivated polio (Tdap-IPV). The study schedule design is to simulate a vaccine efficacy trial to see if single women can participate in studies that mimic actual HIV vaccine studies.

Conditions

  • High Risk for HIV

Interventions

BIOLOGICAL

Tdap - IPV Vaccine

Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, combined with inactivated poliomyelitis vaccine (0.5 ml) will be administered intramuscularly.

BIOLOGICAL

MMR Vaccine

A live attenuated virus vaccine against measles, mumps and rubella (0.5 ml) will be administered intramuscularly.

Sponsors & Collaborators

  • International AIDS Vaccine Initiative

    collaborator NETWORK

  • Zambia-Emory HIV Research Project

    collaborator OTHER

  • Emory University

    lead OTHER

Principal Investigators

  • Susan Allen, MD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2017-05-16
Completion
2017-05-16

Countries

  • Zambia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02589678 on ClinicalTrials.gov